Drug Database
AZ

aztreonam lysine (Cayston / Corus 1020 / AZLI)

✓ Approved

Gilead Sciences, Inc. · 小分子 · 小分子

什么是 aztreonam lysine?

aztreonam lysine 是一种小分子,由Gilead Sciences, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled。

药物档案

商品名Cayston, Corus 1020, AZLI
公司Gilead Sciences, Inc.
药物类别小分子
给药途径Inhaled
状态Approved

治疗适应症

aztreonam lysine 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsRespiratory tract infection✓ Approved
Infections and infestationsPneumonia pseudomonal✓ Approved
Respiratory, thoracic and mediastinal disordersBronchiectasisPhase III

相关研究文献

PubMedFrontiers in oncology2026-11-17

Lactylation-mediated remodeling of spatial immunometabolic niches in lung cancer: metabolic origins, cellular interactions, and molecular mechanisms.

Lin Zihao Z, Che Chengri C, Wang Shuwei S

Hypoxia, abnormal perfusion, and oncogenic signaling increase lactate production in lung cancer and create intercellular fluxes mediated by monocarboxylate transporters. Circulating lactate can be taken up by lung tumors and enter the tricarboxylic acid (TCA) cycle. Lactate therefore acts as a carbon source, a regulator of redox and acid-base homeostasis, and a precursor for lysine L-lactylation. Representative validated modifications include histone H3 lysine 18 lactylation (H3K18la) and histone H4 lysine 5 lactylation (H4K5la) together with nonhistone substrates such as programmed death ligand 1 (PD-L1), hexokinase 2 (HK2), mitochondrial cristae-organizing protein Mic60, and replication protein A1 (RPA1), linking lactylation to transcriptional regulation, protein stability, metabolic adaptation, immune evasion, DNA repair, and treatment resistance in lung cancer. Tumor-derived lactate also reprograms cluster of differentiation 8-positive (CD8+) T cells, regulatory T cells, macrophages, dendritic cells, and cancer-associated fibroblasts across hypoxic cores, invasive fronts, perivascular regions, and tertiary lymphoid structure-associated areas. This review integrates lactate-pool formation, lactylation writers and erasers, intracellular reprogramming, immune-stromal interactions, and spatial niches. It distinguishes metabolic and acidification effects of lactate from covalent lactylation and separates direct causal evidence in lung cancer from spatial associations and cross-cancer mechanistic support. This framework defines a source-to-site chain for studying regional lactate activity and lactylation-dependent phenotypes in lung cancer.

PMID 43041756
阅读全文 →
PubMedBMC bioinformatics2026-11-17

AcetylBench: a deduplicated benchmark dataset reveals systematic performance inflation and cross-database generalisation failure in lysine acetylation site prediction.

Ashraf Muhammad Uzair MU, Khan Shaista S, Sarfraz Mohammad M, Khan Rizwan Hasan RH

Lysine acetylation is a pervasive post-translational modification with critical regulatory roles, yet computational prediction of acetylation sites remains hampered by unreliable benchmarking practices including dataset redundancy and non-independent test set evaluation. We report a systematic investigation demonstrating that three independent sources of metric inflation, including near-ubiquitous sequence redundancy, non-independent test sets, and distribution-locked dimensionality reduction collectively reduced an apparent accuracy of 99.38% to a true cross-database AUC of 0.523, indistinguishable from random classification. Applying CD-HIT at 40% pairwise sequence identity to a dbPTM-derived acetylation dataset, we found that 62.7% of positive and 90.3% of negative sequences are redundant, a level not previously quantified for this task. A comprehensive cross-database benchmark evaluating seven representation strategies (CKSAAP, BLOSUM62, one-hot, ESM-2, ProtBERT, ESM-1v mean-pool, and ESM-1v lysine-position) across two training databases reveals a consistent generalisation failure: within-database cross-validation AUC values of 0.815-0.867 collapse to 0.582-0.607 on a truly independent benchmark. Logistic regression, random forest, and neural network classifiers achieve statistically indistinguishable cross-database performance on identical features, establishing that this failure is driven by feature representations rather than classifier architecture. DeepAcet, using PSSM features computed via PSI-BLAST against a database-independent evolutionary reference, achieves AUC 0.841, substantially exceeding all PLM-based methods trained on identical data (best: AUC 0.705). We release AcetylBench, a rigorously deduplicated benchmark comprising 27,182 positive and 7063 negative sequences, to enable reliable evaluation of future acetylation predictors.

PMID 43040224
阅读全文 →
PubMedExpert opinion on therapeutic targets2026-11-17

Epigenetic Dysregulation in H3K27M diffuse midline glioma: therapeutic vulnerabilities and emerging insights into viral mimicry.

Liou Angela A, Raju Praveen P, Adams Peter D PD

Pediatric diffuse midline glioma (DMG) is a near-lethal childhood brain tumor. The lysine-to-methionine substitution at histone H3 lysine (K) 27 disrupts normal histone post-translational modification, driving global loss of H3K27 trimethylation and widespread reprogramming of chromatin accessibility and transcription that sustain oncogenic cell states. In this review, we synthesize current knowledge on how histone modifications, DNA methylation, and chromatin-remodeling machinery are altered in H3K27M DMG, and summarize therapeutic strategies aimed at targeting each affected epigenetic regulator. We also highlight an emerging therapeutic paradigm in which epigenetic disruption of repetitive-element silencing may create a viral-mimicry vulnerability that can be therapeutically exploited. In our view, viral mimicry represents a promising and potentially powerful therapeutic strategy in H3K27M DMG that exploits an epigenetic vulnerability. Loss of H3K27me3 may weaken repetitive element silencing, likely leaving tumor cells dependent on alternative repressive mechanisms. Disrupting these silencing pathways with epigenetic drug combinations may derepress retrotransposons and activate antiviral sensing, potentially reducing tumor fitness through cell-intrinsic stress and antitumor immune responses. However, clinical translation will require ongoing rigorous preclinical validation, CNS-penetrant agents, biomarkers of epigenetic vulnerability, and resistance monitoring. Future studies must also thoughtfully balance antitumor immunity against neuroinflammatory toxicity.

PMID 43043370
阅读全文 →
PubMedThe Biochemical journal2026-11-17

Carbamylome analysis reveals regulatory roles for lysine carbamylation in β-cell glycolytic and insulin-processing enzymes.

You Youngki Y, Kim Hyeyoon H, Ushakumary Mereena G MG, Gritsenko Marina A MA et al.

In type 1 diabetes (T1D), insulin-producing β cells are destroyed by an autoimmune response driven by pro-inflammatory cytokines. The signaling of these cytokines is partially mediated by post-translational modifications, such as phosphorylation and acetylation. However, the role of other post-translational modifications in β-cell cytokine signaling represents an important knowledge gap. In the context of autoimmune diseases, lysine carbamylation has gained attention for its role in pathogenesis. Here, we investigate possible roles of carbamylation in T1D. We found that pancreata from the T1D model, non-obese diabetic (NOD) mice, at pre-diabetic stage (8-9 weeks old) exhibit 11% carbamylation-positive β cells, whereas non-diabetic CD1 mice have only 5%. Proteomics analysis of the MIN6 insulin-producing cell line treated with a cocktail of three pro-inflammatory cytokines IFNγ + IL-1β + TNFα identified 284 carbamylated peptides from 222 proteins regulated by the cytokine treatment. Integration of carbamylation and acetylation provided a deep view of the cytokine-regulated PTMs and potential points of interplay. A functional-enrichment analysis revealed that carbamylation was enriched in pathways related to autoimmune diseases, metabolism, DNA replication, and protein translation. Moreover, functional testing demonstrated that carbamylation inhibits the glycolytic enzyme aldolase A and the insulin-processing enzyme carboxypeptidase E, identifying a possible role for cytokine-induced β-cell dysfunction. In summary, NOD mice have more carbamylated β cells than CD1 mice, and pro-inflammatory cytokine treatment regulates protein carbamylation in MIN6 cells. These data identified carbamylation as a potential regulatory mechanism for β-cell metabolism and insulin production in insulitis.

PMID 43042510
阅读全文 →
PubMedERJ open research2026-11-17

Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis: a post hoc analysis of the TORNASOL trial.

Li Xue-Shan XS, Sun Xiao-Li XL, Zhu Ya-Nan YN, Guan Wei-Jie WJ et al.

Inhaled aztreonam improves symptoms in bronchiectasis, with baseline bacterial load predicting therapeutic responses in Western populations. Evidence for inhaled tobramycin, a widely used alternative, remained limited in non-Western countries. The objectives of the present study were to investigate how baseline bacterial load modulates symptomatic responses to inhaled tobramycin, and to identify which symptoms improved most favourably in bronchiectasis. A post hoc analysis of the TORNASOL randomised, placebo-controlled trial included 357 adults with bronchiectasis and Pseudomonas aeruginosa in China. Patients received inhaled tobramycin or placebo in two 28-day on-off cycles, with follow-up to day 85. Sputum bacterial load was stratified as high (≥107 CFU·g-1), moderate (105-106 CFU·g-1) and low (<105 CFU·g-1) load. Changes in the total Quality-of-Life Bronchiectasis Respiratory Symptom Scores (QoL-B-RSS; minimal clinically important difference (MCID): 8 points) and individual symptom domains were analysed, with Bonferroni correction applied to the nine-item-level comparisons (adjusted α=0.0056). At baseline, 68.3% of patients had high and 29.1% had moderate bacterial load, with >75% of high-load patients remaining in the same category. Compared with placebo, inhaled tobramycin yielded significant QoL-B-RSS improvements exceeding MCID in the high-load subgroup (mean difference 8.28, 95% CI 4.46-12.09; p<0.0001) and below the MCID in the moderate-load subgroup (mean difference 6.51, 95% CI 1.31-11.72; p=0.0065) at day 29, with improvements at day 85. Cough, sputum production/purulence and chest congestion were the symptoms exhibiting most favourable responses, particularly in the high-load subgroup. High bacterial load was associated with numerically greater symptomatic improvements to inhaled tobramycin in bronchiectasis. These hypothesis-generating findings warrant further investigation.

PMID 43041818
阅读全文 →
PubMediScience2026-11-17

Targeting SOST-LRRC15 axis impairs triple-negative breast cancer progression by regulating WNT signaling and EMT.

Dai Chunfei C, Yang Huimin H, Zhao Rongjie R, Qianjiang Haoyue H et al.

Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Although sclerostin (SOST) is a well-established WNT regulator in bone metabolism, its role in cancer is poorly understood. Here, we identify SOST as a context-dependent oncogenic driver in TNBC. The Cancer Genome Atlas (TCGA) analysis revealed SOST is highly upregulated in TNBC and correlates with poor survival. Functional studies demonstrated that SOST drives TNBC proliferation, migration, and invasion by activating WNT/β-catenin signaling and epithelial-mesenchymal transition (EMT). Using co-immunoprecipitation-mass spectrometry, we identified leucine-rich repeat-containing protein 15 (LRRC15) as a key SOST-binding partner facilitating its secretion, with co-expression predicting poor prognosis. We further uncovered that SOST function is regulated by P300-mediated acetylation at lysine 134 (K134). Therapeutic targeting of SOST using a specific aptamer or the small-molecule inhibitor SOSTi effectively suppressed TNBC malignancy. Our findings establish an SOST-LRRC15 axis promoting TNBC progression through WNT/EMT activation, positioning SOST as a promising therapeutic target.

PMID 43041716
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多aztreonam lysine